PRX-03140 is a

partial agonist In pharmacology, partial agonists are drugs that bind to and activate a given receptor, but have only partial efficacy at the receptor relative to a full agonist. They may also be considered ligands which display both agonistic and antagonis ...

(18% relative to

5-HT Serotonin () or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter. Its biological function is complex and multifaceted, modulating mood, cognition, reward, learning, memory, and numerous physiological processes such as vomiting and va ...

) of the 5-HT₄ receptor that was developed by EPIX Pharmaceuticals for Alzheimer's disease. Epix Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) was a

pharmaceutical company The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate sympto ...

based in Lexington,

Massachusetts Massachusetts (Massachusett: ''Muhsachuweesut Massachusett_writing_systems.html" ;"title="nowiki/> məhswatʃəwiːsət.html" ;"title="Massachusett writing systems">məhswatʃəwiːsət">Massachusett writing systems">məhswatʃəwiːsət'' En ...

. In 2009, Epix was in the process of asset liquidation due to insufficient funds to stay afloat. Nanotherapeutics, Inc. acquired the product in 2010 conducting one clinical study in PTSD patients. In 2018 the product was transferred to Nanoshift, LLC. Nanoshift LLC and Nanopharmaceutics, Inc.
www.nanopharmaceutics.com
continue to support clinical studies. It has been tested in six Phase 1 and Phase 2 clinical trials.

References

Carboxamides Nootropics 1-Piperidinyl compounds Serotonin receptor agonists Thienopyridines Isopropyl compounds {{nervous-system-drug-stub